Introduction
activation of transmembrane scramblase activity at this concentration of calcium, resulting in non-specific exposure of PS, are some of the limitations associated with the use of annexin V in molecular apoptosis imaging [12] .
The aforementioned studies attempted to seek alternatives to annexin V, and demonstrated that fluorescent dyes [13] , the zincdipicolylamine co-ordination complex [14] , dye-labelled cationic liposome [15] , peptide-labelled nanoparticles [16] , short peptides [17] and larger proteins including lactadherine and the C2A domain of synaptotagmin I [18, 19] [20] . 
can detect the PS molecules on the surfaces of apoptotic cells. Peptides specific to molecules do have advantages over proteins and antibodies for a number of reasons, including superior stability, non-immunogenicity, low cost, easy labelling and rapid clearance and tissue penetration

Thus, the discovery of a peptide endowed with PS specificity could be extremely useful, and may result in the development of a diagnostic means for the non-invasive imaging of apoptosis under a variety of clinical conditions, and as a carrier molecule for targeted therapy. Importantly, the construction of nanoparticles coated with multiple numbers of peptides will enable the multivalent interaction of peptides with its target molecule, thus enhancing the affinity of the peptide to a considerable extent. The principal objective of the present study was to discover novel PS-recognizing peptidic ligands that can be utilized for a variety of applications, including the molecular imaging of apoptosis or targeting moieties in PS-exposed cells. We screened a phage display peptide library via the conventional method of repeated biopanning of the phage library to PS-coated plates prior to examining the enrichment of the consensus peptide sequences. The ability of the identified phage clone and its corresponding peptide to recognize and bind to the PS molecules on the apoptotic cell surface were demonstrated herein. The targeting of fluorescein-labelled peptides to apoptotic tumour cells following systemic administration into tumour-bearing mice, and its possible use in the in vivo detection of apoptosis by using optical imaging system were evaluated herein.
Materials and methods
Materials
L-␣-phosphatidylserine (PS) and L-␣-phosphatidylcholine (PC) were purchased from Avanti Polar Lipids, Inc. USA. The his-tagged annexin V protein was purified from Escherichia coli transformed with cDNA encoding for annexin V in a pET29b expression vector system (Novagen, Madison, WI).
Cell culture
H460 and H157 human lung cancer cells and U937 leukaemia cells were maintained in RMPI 1640 medium containing 10% foetal bovine serum supplemented with antibiotics.
Screening of PS binding phages
Phage clone binding to apoptotic cells
The binding of the selected phage clone to various apoptotic cells was assessed by a phage plaque assay. Apoptosis was induced in H460, H157 and U937 cells via treatment with etoposide (50 µm) (Sigma). U937 cells were treated for 4 hrs, whereas H460 and H157 cells were treated for 18 hrs. In order to ensure the exposure of PS molecules on the apoptotic cell surfaces, fluorescence activated cell sorting (FACS) analyses were conducted after annexin V (BD Biosciences
)
FACS analysis
Results
Screening of M13 phage library and validation of selected phage clones
The M13 phage library evidencing CX7C random peptides was screened to enrich phages that bind selectively to PS over PC. The simple schematic diagram of selection strategy is shown in Fig. 1A . Phospholipids coating the ELISA plates were assessed via the annexin V binding test prior to the initiation of biopanning rounds (Fig. 1B) (Fig. 1C) Fig. 2A) and phage-ELISA assay (Fig. 2B) (Fig. 2C) plates, thereby indicating the possibility of phage binding to the PS molecule exposed on the apoptotic cell surfaces. Additionally, the binding of the selected phage clone, CLSYYPSYC, to the PS-coated plate was inhibited by annexin V (Fig. 2D) . (Fig. 3A, B (Fig. 3D) 
Binding of phage to apoptotic cells
and C). PS exposure in the apoptotic cells was confirmed via FACS analysis using annexin V staining. Some of the cancer cell lines, B16F10 and MCF-7, which evidenced minimal PS exposure after etoposide treatment, also exhibited less significant binding of the phage to the treated cells versus the untreated cells (data not shown). The specificity of interaction to PS molecules on the surfaces of apoptotic cells was verified via the inhibition of phage binding by annexin V
in H460 cells. However, we were unable to demonstrate the PS specificity of phage binding to apoptotic cells using the PS liposome in the inhibition study. The M13 phage library itself evidenced increased binding to apoptotic cells in the presence of the PS liposome (data not shown). Furthermore, the specificity of phage binding was also verified via the inhibition of phage binding to apoptotic H460 cells in the presence of synthesized peptides, but not by the irrelevant peptide (Fig. 3D). Additionally, the binding of the phage clone to PS was unaffected by 4 mM ethylenediaminetetraacetic acid (EDTA), thereby indicating calcium independency in binding to PS molecules (data not shown).
Peptide binding to apoptotic cells
The ability of the synthesized peptide to distinguish between apoptotic and non-apoptotic cells was assessed via both FACS analysis and fluorescence microscopy. Fluorescence-labelled CLSYYPSYC peptide binding was observed in nearly 40% of the H460 cells treated with etoposide, but not to the untreated cells on the FACS analysis (Fig. 4A). Annexin V staining indicated that more than 80% of treated cells are apoptotic. The FACS data in Fig. 3A could represent this result. This result suggests that annexin V with four well-defined PS-binding sites may bind strongly to apoptotic cells than the peptide. Similar results were obtained when the etoposide-treated A549 and H157 cells were utilized (data not shown). The unrelated peptide used in the experiment (control peptide) evidenced no binding to the treated cells. Fluorescence microscopy indicated that the binding of the peptide to the etoposide-treated cells was significantly higher than to the untreated cells (Fig. 4B). The cellular distribution of peptide to apoptotic cells revealed that discrete regions of the apoptotic cell membrane were stained by peptide. Many cells exhibited colocalization of signals when costained with peptide and annexin VAlexa 594 (Fig. 4B). The confocal microscopy performed on apoptotic H460 cells after staining with fluorescein-labelled CLSYYPSYC and annexinV Alexa fluor 568 further confirmed the colocalization of annexin V and peptide (Fig. 4C). The binding/recognition of PS molecules by peptide occurred regardless of the presence or absence of calcium ions (data not shown).
Peptide homing to H460 cell tumour xenografts and optical imaging
We assessed the ability of the CLSYYPSYC peptide to detect cell apoptosis in vivo, and its possible application in the molecular imaging of apoptosis using an H460 (Fig. 6A) . Presence of apoptotic/necrotic areas inside (Fig. 6B) .
Discussion
In the present study, [25] . Tumour vasculature is a suitable target for cancer therapy due to its non-malignant nature and thus, low probability to evidence drug-resistance [26] . Thus, the tumour vasculature is more accessible to anticancer drugs and evidences a more intrinsic amplification mechanism [26] . Thus, the examination of CLSYYPSYC peptide as carrier molecule for anticancer drugs to tumour vessels may prove an interesting area for future studies.
Recently, two studies described the identification of PS-recognizing peptides using phage display technique [27, 28] 
